{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:53:31Z","timestamp":1781654011889,"version":"3.54.5"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-026-01599-2","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:27:32Z","timestamp":1781188052000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimized post-GWAS analysis identifies therapeutic targets for essential thrombocythemia and polycythemia vera"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3271-0896","authenticated-orcid":false,"given":"Xiaoli","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixi","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixian","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2572-6495","authenticated-orcid":false,"given":"Xiaofan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"1599_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury, J. D. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia 36, 1703\u20131719 (2022).","journal-title":"Leukemia"},{"key":"1599_CR2","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber, D. A. et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140, 1200\u20131228 (2022).","journal-title":"Blood"},{"key":"1599_CR3","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.27216","volume":"99","author":"A Tefferi","year":"2024","unstructured":"Tefferi, A., Vannucchi, A. M. & Barbui, T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am. J. Hematol. 99, 697\u2013718 (2024).","journal-title":"Am. J. Hematol."},{"key":"1599_CR4","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter, E. J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054\u20131061 (2005).","journal-title":"Lancet"},{"key":"1599_CR5","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"FP Robert Kralovics","year":"2005","unstructured":"Robert Kralovics, F. P. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779\u20131790 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1599_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ajh.23617","volume":"89","author":"T Barbui","year":"2014","unstructured":"Barbui, T. et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am. J. Hematol. 89, 199\u2013202 (2014).","journal-title":"Am. J. Hematol."},{"key":"1599_CR7","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1182\/blood-2017-06-782037","volume":"130","author":"J Nangalia","year":"2017","unstructured":"Nangalia, J. & Green, A. R. Myeloproliferative neoplasms: from origins to outcomes. Blood 130, 2475\u20132483 (2017).","journal-title":"Blood"},{"key":"1599_CR8","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1182\/blood.2022017578","volume":"141","author":"D Luque Paz","year":"2023","unstructured":"Luque Paz, D., Kralovics, R. & Skoda, R. C. Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood 141, 1909\u20131921 (2023).","journal-title":"Blood"},{"key":"1599_CR9","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s41576-021-00387-z","volume":"22","author":"WR Reay","year":"2021","unstructured":"Reay, W. R. & Cairns, M. J. Advancing the use of genome-wide association studies for drug repurposing. Nat. Rev. Genet. 22, 658\u2013671 (2021).","journal-title":"Nat. Rev. Genet."},{"key":"1599_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrd.2016.230","volume":"16","author":"R Santos","year":"2017","unstructured":"Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov. 16, 19\u201334 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1599_CR11","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ng.3314","volume":"47","author":"MR Nelson","year":"2015","unstructured":"Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856\u2013860 (2015).","journal-title":"Nat. Genet."},{"key":"1599_CR12","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41588-018-0066-3","volume":"50","author":"C Wijmenga","year":"2018","unstructured":"Wijmenga, C. & Zhernakova, A. The importance of cohort studies in the post-GWAS era. Nat. Genet. 50, 322\u2013328 (2018).","journal-title":"Nat. Genet."},{"key":"1599_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ajhg.2017.06.005","volume":"101","author":"PM Visscher","year":"2017","unstructured":"Visscher, P. M. et al. 10 Years of GWAS discovery: biology, function, and translation. Am. J. Hum. Genet. 101, 5\u201322 (2017).","journal-title":"Am. J. Hum. Genet."},{"key":"1599_CR14","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1053\/j.gastro.2023.01.028","volume":"164","author":"J Bourgault","year":"2023","unstructured":"Bourgault, J. et al. Proteome-wide mendelian randomization identifies causal links between blood proteins and acute pancreatitis. Gastroenterology 164, 953\u2013965 e953 (2023).","journal-title":"Gastroenterology"},{"key":"1599_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33675-1","volume":"13","author":"L Chen","year":"2022","unstructured":"Chen, L. et al. Systematic Mendelian randomization using the human plasma proteome to discover potential therapeutic targets for stroke. Nat. Commun. 13, 6143 (2022).","journal-title":"Nat. Commun."},{"key":"1599_CR16","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1093\/brain\/awad070","volume":"146","author":"J Lin","year":"2023","unstructured":"Lin, J., Zhou, J. & Xu, Y. Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis. Brain 146, 3364\u20133372 (2023).","journal-title":"Brain"},{"key":"1599_CR17","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/s41588-020-0682-6","volume":"52","author":"J Zheng","year":"2020","unstructured":"Zheng, J. et al. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nat. Genet. 52, 1122\u20131131 (2020).","journal-title":"Nat. Genet."},{"key":"1599_CR18","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.ajhg.2022.04.001","volume":"109","author":"V Zuber","year":"2022","unstructured":"Zuber, V. et al. Combining evidence from Mendelian randomization and colocalization: Review and comparison of approaches. Am. J. Hum. Genet. 109, 767\u2013782 (2022).","journal-title":"Am. J. Hum. Genet."},{"key":"1599_CR19","doi-asserted-by":"publisher","first-page":"e1004383","DOI":"10.1371\/journal.pgen.1004383","volume":"10","author":"C Giambartolomei","year":"2014","unstructured":"Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 10, e1004383 (2014).","journal-title":"PLoS Genet."},{"key":"1599_CR20","doi-asserted-by":"publisher","first-page":"k601","DOI":"10.1136\/bmj.k601","volume":"362","author":"NM Davies","year":"2018","unstructured":"Davies, N. M., Holmes, M. V. & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 362, k601 (2018).","journal-title":"BMJ"},{"key":"1599_CR21","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","volume":"613","author":"MI Kurki","year":"2023","unstructured":"Kurki, M. I. et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 613, 508\u2013518 (2023).","journal-title":"Nature"},{"key":"1599_CR22","doi-asserted-by":"publisher","first-page":"D977","DOI":"10.1093\/nar\/gkac1010","volume":"51","author":"E Sollis","year":"2023","unstructured":"Sollis, E. et al. The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource. Nucleic Acids Res. 51, D977\u2013D985 (2023).","journal-title":"Nucleic Acids Res."},{"key":"1599_CR23","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1038\/s41588-021-00978-w","volume":"53","author":"E Ferkingstad","year":"2021","unstructured":"Ferkingstad, E. et al. Large-scale integration of the plasma proteome with genetics and disease. Nat. Genet. 53, 1712\u20131721 (2021).","journal-title":"Nat. Genet."},{"key":"1599_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","volume":"622","author":"BB Sun","year":"2023","unstructured":"Sun, B. B. et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature 622, 329\u2013338 (2023).","journal-title":"Nature"},{"key":"1599_CR25","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s41588-021-00913-z","volume":"53","author":"U Vosa","year":"2021","unstructured":"Vosa, U. et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat. Genet. 53, 1300\u20131310 (2021).","journal-title":"Nat. Genet."},{"key":"1599_CR26","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41586-023-06563-x","volume":"622","author":"GH Eldjarn","year":"2023","unstructured":"Eldjarn, G. H. et al. Large-scale plasma proteomics comparisons through genetics and disease associations. Nature 622, 348\u2013358 (2023).","journal-title":"Nature"},{"key":"1599_CR27","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/sim.3034","volume":"27","author":"DA Lawlor","year":"2008","unstructured":"Lawlor, D. A., Harbord, R. M., Sterne, J. A., Timpson, N. & Davey Smith, G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat. Med. 27, 1133\u20131163 (2008).","journal-title":"Stat. Med."},{"key":"1599_CR28","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/s41588-021-00923-x","volume":"53","author":"JL Min","year":"2021","unstructured":"Min, J. L. et al. Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation. Nat. Genet. 53, 1311\u20131321 (2021).","journal-title":"Nat. Genet."},{"key":"1599_CR29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10654-021-00757-1","volume":"36","author":"AR Carter","year":"2021","unstructured":"Carter, A. R. et al. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. Eur. J. Epidemiol. 36, 465\u2013478 (2021).","journal-title":"Eur. J. Epidemiol."},{"key":"1599_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7691","volume":"6","author":"W Tapper","year":"2015","unstructured":"Tapper, W. et al. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nat. Commun. 6, 6691 (2015).","journal-title":"Nat. Commun."},{"key":"1599_CR31","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrc2439","volume":"8","author":"RG Ramsay","year":"2008","unstructured":"Ramsay, R. G. & Gonda, T. J. MYB function in normal and cancer cells. Nat. Rev. Cancer 8, 523\u2013534 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"1599_CR32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrg3185","volume":"13","author":"C Vogel","year":"2012","unstructured":"Vogel, C. & Marcotte, E. M. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 13, 227\u2013232 (2012).","journal-title":"Nat. Rev. Genet."},{"key":"1599_CR33","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cell.2016.03.014","volume":"165","author":"Y Liu","year":"2016","unstructured":"Liu, Y., Beyer, A. & Aebersold, R. On the Dependency of Cellular Protein Levels on mRNA Abundance. Cell 165, 535\u2013550 (2016).","journal-title":"Cell"},{"key":"1599_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature07242","volume":"455","author":"D Baek","year":"2008","unstructured":"Baek, D. et al. The impact of microRNAs on protein output. Nature 455, 64\u201371 (2008).","journal-title":"Nature"},{"key":"1599_CR35","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/emboj.2009.97","volume":"28","author":"P Garcia","year":"2009","unstructured":"Garcia, P. et al. Reduced c-Myb activity compromises HSCs and leads to a myeloproliferation with a novel stem cell basis. EMBO J. 28, 1492\u20131504 (2009).","journal-title":"EMBO J."},{"key":"1599_CR36","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1182\/blood.2022019138","volume":"141","author":"ML Clarke","year":"2023","unstructured":"Clarke, M. L. et al. MYB insufficiency disrupts proteostasis in hematopoietic stem cells, leading to age-related neoplasia. Blood 141, 1858\u20131870 (2023).","journal-title":"Blood"},{"key":"1599_CR37","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12105-024-01719-1","volume":"18","author":"AS Fisch","year":"2024","unstructured":"Fisch, A. S. et al. Comparative Analysis of MYB Expression by Immunohistochemistry and RNA Sequencing in Clinical Gene Fusion Detection in Adenoid Cystic Carcinoma. Head. Neck Pathol. 18, 114 (2024).","journal-title":"Head. Neck Pathol."},{"key":"1599_CR38","first-page":"3976","volume":"53","author":"SH Kaufmann","year":"1993","unstructured":"Kaufmann, S. H., Desnoyers, S., Ottaviano, Y., Davidson, N. E. & Poirier, G. G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 53, 3976\u20133985 (1993).","journal-title":"Cancer Res."},{"key":"1599_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.seminoncol.2023.09.005","volume":"51","author":"Y Zeng","year":"2024","unstructured":"Zeng, Y., Arisa, O., Peer, C. J., Fojo, A. & Figg, W. D. PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics. Semin Oncol. 51, 19\u201324 (2024).","journal-title":"Semin Oncol."},{"key":"1599_CR40","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord, C. J. & Ashworth, A. PARP inhibitors: Synthetic lethality in the clinic. Science 355, 1152\u20131158 (2017).","journal-title":"Science"},{"key":"1599_CR41","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1158\/1078-0432.CCR-15-2351","volume":"22","author":"KW Pratz","year":"2016","unstructured":"Pratz, K. W. et al. Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms. Clin. Cancer Res. 22, 3894\u20133902 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1599_CR42","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1182\/blood-2017-05-784942","volume":"130","author":"M Nieborowska-Skorska","year":"2017","unstructured":"Nieborowska-Skorska, M. et al. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood 130, 2848\u20132859 (2017).","journal-title":"Blood"},{"key":"1599_CR43","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1158\/1078-0432.CCR-16-1274","volume":"23","author":"KW Pratz","year":"2017","unstructured":"Pratz, K. W. et al. A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. Clin. Cancer Res. 23, 899\u2013907 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1599_CR44","doi-asserted-by":"publisher","first-page":"38080","DOI":"10.1074\/jbc.M112.394288","volume":"287","author":"SY Qin","year":"2012","unstructured":"Qin, S. Y. et al. Malectin forms a complex with ribophorin I for enhanced association with misfolded glycoproteins. J. Biol. Chem. 287, 38080\u201338089 (2012).","journal-title":"J. Biol. Chem."},{"key":"1599_CR45","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.yexmp.2006.07.004","volume":"81","author":"HF Mark","year":"2006","unstructured":"Mark, H. F. et al. Chronic idiopathic myelofibrosis (CIMF) resulting from a unique 3;9 translocation disrupting the janus kinase 2 (JAK2) gene. Exp. Mol. Pathol. 81, 217\u2013223 (2006).","journal-title":"Exp. Mol. Pathol."},{"key":"1599_CR46","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1182\/hematology.2024000576","volume":"2024","author":"A Chee","year":"2024","unstructured":"Chee, A. & Mead, A. J. Molecular profiling in MPN: who should have it and why? Hematol. Am. Soc. Hematol. Educ. Program 2024, 524\u2013534 (2024).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"1599_CR47","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3324\/haematol.2023.283987","volume":"110","author":"VY Ling","year":"2025","unstructured":"Ling, V. Y., Heidel, F. H. & Bywater, M. J. Pathogenesis and management of high molecular risk myeloproliferative neoplasms. Haematologica 110, 863\u2013876 (2025).","journal-title":"Haematologica"},{"key":"1599_CR48","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/ajh.27002","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi, A. & Barbui, T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 98, 1465\u20131487 (2023).","journal-title":"Am. J. Hematol."},{"key":"1599_CR49","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1113\/jphysiol.2010.195057","volume":"589","author":"W Jelkmann","year":"2011","unstructured":"Jelkmann, W. Regulation of erythropoietin production. J. Physiol. 589, 1251\u20131258 (2011).","journal-title":"J. Physiol."},{"key":"1599_CR50","doi-asserted-by":"crossref","unstructured":"Kaushansky, K. Thrombopoietin, the Primary Regulator of Platelet Production: From Mythos to Logos, a Thirty-Year Journey. Biomolecules 14, 489 (2024).","DOI":"10.3390\/biom14040489"},{"key":"1599_CR51","doi-asserted-by":"publisher","unstructured":"Birney, E. Mendelian Randomization. Cold Spring Harb Perspect Med, 12, https:\/\/doi.org\/10.1101\/cshperspect.a041302 (2022).","DOI":"10.1101\/cshperspect.a041302"},{"key":"1599_CR52","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1101\/gad.17269211","volume":"25","author":"J Zuber","year":"2011","unstructured":"Zuber, J. et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 25, 1628\u20131640 (2011).","journal-title":"Genes Dev."},{"key":"1599_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05838-9","volume":"22","author":"A Ghelli Luserna di Ror\u00e0","year":"2024","unstructured":"Ghelli Luserna di Ror\u00e0, A. et al. Exploring the role of PARP1 inhibition in enhancing antibody-drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions. J. Transl. Med. 22, 1062 (2024).","journal-title":"J. Transl. Med."},{"key":"1599_CR54","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cell.2014.02.019","volume":"157","author":"S Gr\u00f6schel","year":"2014","unstructured":"Gr\u00f6schel, S. et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell 157, 369\u2013381 (2014).","journal-title":"Cell"},{"key":"1599_CR55","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14740\/jh1042","volume":"11","author":"Z McKinnell","year":"2022","unstructured":"McKinnell, Z., Karel, D., Tuerff, D., Sh Abrahim, M. & Nassereddine, S. Acute Myeloid Leukemia Following Myeloproliferative Neoplasms: A Review of What We Know, What We Do Not Know, and Emerging Treatment Strategies. J. Hematol. 11, 197\u2013209 (2022).","journal-title":"J. Hematol."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01599-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01599-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01599-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:06:17Z","timestamp":1781651177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01599-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1599"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01599-2","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"342"}}